BENDAMUSTINE HYDROCHLORIDE is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and has 3 approved and 16 investigational indications. It is grouped under the following drug class(es): Alkylating agents, Antineoplastic agents and Cytotoxics. Its therapeutic use is listed as antineoplastics. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Treanda, Ribomustin and Bendeka. Its PubChem CID is 77082.
Bendamustine hydrochloride
| CAS No | 3543-75-7 |
|---|---|
| Molecular Formula | C16H22Cl3N3O2 |
| Molecular Weight | 394.7 g/mol |
| Synonyms | 4-{5-[Bis(2-chloroethyl)amino]-1-methyl-1H-benzimidazol-2-yl}butanoic acid hydrochloride |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
BENDAMUSTINE HYDROCHLORIDE is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and has 3 approved and 16 investigational indications.
The listed CAS number is 3543-75-7.
The listed molecular formula is C16H22Cl3N3O2.
The listed molecular weight is 394.7 g/mol.
4-{5-[Bis(2-chloroethyl)amino]-1-methyl-1H-benzimidazol-2-yl}butanoic acid hydrochloride.
The source lists Treanda, Ribomustin and Bendeka.